New era of direct blood
oxygenation for respiratory support

INSPIRA directly oxygenates the blood, bypassing the lungs to provide respiratory support to patients

Augmented Respiration Technology preempts the need for Mechanical Ventilation (MV) which requires intubation and sedation

Discover INSPIRA ART

Advanced oxygenation for superior patient care

Millions are affected by acute respiratory distress (ARD)

Mechanical ventilation (MV) is one of the last resort interventions used to treat patients in intensive care units

Hospitals face dilemmas between saving a patient and exposing them to the high risks and complications associated with MV

Doctors seek a solution to treat patients whilst awake & mobile

Advanced oxygenation for superior patient care

Millions are affected by acute respiratory distress (ARD)

Mechanical ventilation (MV) is one of the last resort interventions used to treat patients in intensive care units

Hospitals face dilemmas between saving a patient and exposing them to the high risks and complications associated with MV

Doctors seek a solution to treat patients whilst awake & mobile

Dilemmas With Mechanical Ventilation

MV is a machine that artificially inflates the lungs with oxygenized gas, as a measure to save ARD patients

High Risks

1 in 2 patients die 2 in 5 suffer complications

MV Limited to ICU

Patient intubation & sedation requires highly specialized staff

Growing Costs

Hundreds of $billions in healthcare expenditure

Expensive

Current ICU costs of treatment may exceed US$ 10K per day

Stagnant

No innovative alternative developed in over 70 years

Probelm with intubation and MV

50%

Mortality rate

40%

Readmission (long-term physical health impairments)

25%

Ventilator associated lung injury (VALI)

25%

Ventilator associated pneumonia (VAP)

50%

Of hospital days - weaning off MV

80%

Respiratory muscle wasting & pressure wounds

100%

Medically induced coma

* Statistics have been rounded

ART 500 Respiratory First Line Treatment

Treated patients

Treated patients

Are awake & mobile

Applicable

Applicable

In most clinical settings Hospitals: ICU’s, ER’s, General Wards & Clinics

Ambulatory

Ambulatory

Intensive Care Ambulances & Military

CONTACT US

Competitive Advantage

ECMO
MV
ART

Preempts MV (Patient Treated Awake)

Ambulatory & General Wards

ICU Applicable

Minimally Invasive (Not require radiography)

No blood thinners

Low risks & complications

Not require highly specialized staff

Weaning /Rehabilitation Risk

Weaning /Rehabilitation Risk

High
High
N/A

ART Benefits

  • Expanding care to all hospital settings
  • Emergency & ambulatory situations
  • Rural hospitals & clinics
  • Patients treated while awake & mobile
  • Reduced patient risk in relation to MV
  • No need for weaning
  • Minimally invasive (No radiography)
  • Reduced hospital days & costs
  • Not require highly specialized staff

Accomplishments

PCT
Patents

IIA Grant Awarded

Pre-Clinical Studies

PCT
Patents

IIA Grant Awarded

Pre-Clinical Studies

Investor Relations

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy
CONTACT US

News

Inspira Technologies Appoints Benad Goldwasser as Chairman of the Board
Published on February 24, 2021
READ MORE
Inspira Technologies Files U.S. Patent Application for its Innovative Respiratory Support Technology; Engages Leading…
Published on December 3, 2020
READ MORE
Sheba and Inspira Technologies implement respiratory treatment for Covid-19 patients
Published on February 17, 2021
READ MORE
ALL NEWS

Co-Founders

Experienced in respiratory medicine, clinical development and regulatory expertise in medical devices

Joe Hayon, MBA

Co-Founder | President & CFO

Former CFO, CIO and Corp Manager of Global Medical, EMS and Defense companies

Elscint (Formerly NASDAQ & TSE : ELT, CT technology acquired by Philips Electronics, NYSE : PHG, MRI technology acquired by GE, NYSE : GE)

Sanmina – Medical Division (NASDAQ: SANM)
Arazim Integrated Technologies Group
Plasan Group (Plasan Sasa, Plasan North America, Kazak, Plasan Carbon Composites

Dr. Udi Nussinovitch, MD PhD

Co-Founder | CMO

Cardiology Fellow with ICU experience, senior diving and hyperbaric physician

Sheba Medical Center, Israel Naval Medical Institute, Technion Institute of Technology, Meir Medical Center, Tel Aviv University

Publications Edited:
The Heart in Rheumatic, Autoimmune and Inflammatory Diseases, 2017.
Emerging Technologies for Heart Diseases, 2020.

Dagi Ben-Noon, BSc

Co-Founder | CEO

Multi industry experience in leading R&D activities & cultivating in-house innovation.

Highly experienced managing R&D, product design & development, system engineering & supply chain management

Former Co-Founder, COO and Director of Nano Dimension (NASDAQ : NNDM)

Executive Medical Board

Dr. Yigal Kasif, MD

Chief ECMO Advisor

Cardiac Surgeon & Director of ECMO Israel
Adult Cardiac Surgery, Heart Transplantation,
Assist Device & ECMO, Intensive Care Treatment
Sheba Tel Ha Shomer Hospital, Cambridge University, UCLA, Hebrew University of Jerusalem

Prof. Joseph Kost, D.Sc MBA

Chief Biomedical Advisor

Professor and Senior Advisor to the President on International Research Strategies,
Chair of Biomedical Engineering and past Dean of the Faculty of Engineering Sciences at Ben-Gurion University

Prof Eli Gabbay, MBBS MD FRACP

Chief Respiratory Advisor

Respiratory Physician
Professor of Medicine, School of Medicine, Fremantle, University of Notre Dame, Australia
Professor of Medicine, School of Medicine, University of Western Australia

Dr. Orit Cohen Jacob

Clinical & Research Consulting

Dr. Orit is a veterinary surgeon with a unique speciality in Laboratory animal science.
She has 23 years of experience in research, 16 years in IIBR – Israeli Prime minister’s office, founding and heading a large, state of the art, pre-clinical facility, in accordance with GMP/ GLP quality requirements (small and large animals).

Dr. Orit was the first women elected as chairwomen of the National Animal Experiments Ethics Committee, responsible for all regulations in Israel for animal lab experiments.

 

Subscribe for our newsletter updates

Text that explains that we send updates once a month and that we do not bother or send spam


By submitting the form you agree to receive emails from us and to our Privacy Policy and the Terms of Use

Keep me updated

We would love to talk

CONTACT US